| TNF signaling pathway |
2.43 |
0.00e+0 |
103/112 (91.96%) |
CXCL3;CXCL2;CCL20;...
|
| IL-17 signaling pathway |
2.39 |
0.00e+0 |
84/94 (89.36%) |
CXCL8;CXCL3;FOSL1;...
|
| Viral protein interaction with cytokine and cytokine re... |
2.19 |
0.00e+0 |
84/100 (84%) |
CXCL8;CXCL3;TNFRSF10B;...
|
| Prostate cancer |
2.16 |
0.00e+0 |
93/97 (95.88%) |
PDGFA;CDKN1A;PIK3CD;...
|
| Rheumatoid arthritis |
2.13 |
2.88e-3 |
78/93 (83.87%) |
CXCL8;CXCL3;VEGFA;...
|
| Epithelial cell signaling in Helicobacter pylori infect... |
2.09 |
2.40e-3 |
62/70 (88.57%) |
CXCL8;PAK1;CXCL3;...
|
| C-type lectin receptor signaling pathway |
2.07 |
4.12e-3 |
93/104 (89.42%) |
PAK1;NFATC3;RELB;...
|
| Lipid and atherosclerosis |
2.01 |
3.60e-3 |
190/215 (88.37%) |
CXCL8;NFATC3;CXCL3;...
|
| NF-kappa B signaling pathway |
1.99 |
3.20e-3 |
90/104 (86.54%) |
CXCL8;RELB;CXCL3;...
|
| Mineral absorption |
1.99 |
2.88e-3 |
48/60 (80%) |
HMOX1;STEAP1;MT1X;...
|
| Kaposi sarcoma-associated herpesvirus infection |
1.97 |
3.93e-3 |
172/193 (89.12%) |
CXCL8;NFATC3;CXCL3;...
|
| AGE-RAGE signaling pathway in diabetic complications |
1.97 |
3.60e-3 |
97/100 (97%) |
CXCL8;VEGFA;PIK3CD;...
|
| T cell receptor signaling pathway |
1.94 |
4.44e-3 |
93/104 (89.42%) |
PAK1;NFATC3;PIK3CD;...
|
| NOD-like receptor signaling pathway |
1.90 |
4.12e-3 |
145/181 (80.11%) |
CXCL8;CXCL3;CXCL2;...
|
| Natural killer cell mediated cytotoxicity |
1.89 |
5.77e-3 |
99/131 (75.57%) |
PAK1;TNFRSF10B;PIK3CD;...
|
| Thyroid cancer |
1.86 |
8.11e-3 |
36/37 (97.3%) |
CDKN1A;MYC;GADD45A;...
|
| Bladder cancer |
1.86 |
9.33e-3 |
40/41 (97.56%) |
CXCL8;VEGFA;HBEGF;...
|
| Focal adhesion |
1.85 |
8.81e-3 |
180/201 (89.55%) |
PAK1;LAMC2;VEGFA;...
|
| Cytokine-cytokine receptor interaction |
1.82 |
1.06e-2 |
246/295 (83.39%) |
CXCL8;CXCL3;TNFRSF10B;...
|
| HIF-1 signaling pathway |
1.81 |
1.08e-2 |
105/109 (96.33%) |
HMOX1;VEGFA;CDKN1A;...
|
| Legionellosis |
1.80 |
1.17e-2 |
51/57 (89.47%) |
CXCL8;CXCL3;ITGAM;...
|
| Protein processing in endoplasmic reticulum |
1.80 |
1.11e-2 |
127/171 (74.27%) |
HERPUD1;HSPA6;DDIT3;...
|
| MAPK signaling pathway |
1.80 |
1.07e-2 |
272/294 (92.52%) |
PAK1;NFATC3;RELB;...
|
| Leukocyte transendothelial migration |
1.78 |
1.50e-2 |
90/114 (78.95%) |
ITGAM;PIK3CD;ACTN1;...
|
| Fluid shear stress and atherosclerosis |
1.77 |
1.61e-2 |
123/139 (88.49%) |
HMOX1;VEGFA;PDGFA;...
|
| Ferroptosis |
1.77 |
1.61e-2 |
36/41 (87.8%) |
HMOX1;SLC39A14;MAP1LC3B;...
|
| PI3K-Akt signaling pathway |
1.75 |
1.87e-2 |
317/354 (89.55%) |
LAMC2;VEGFA;PDGFA;...
|
| Salmonella infection |
1.74 |
1.96e-2 |
198/249 (79.52%) |
CXCL8;PAK1;TNFRSF10B;...
|
| ErbB signaling pathway |
1.72 |
2.49e-2 |
79/85 (92.94%) |
PAK1;HBEGF;CDKN1A;...
|
| Collecting duct acid secretion |
1.72 |
2.47e-2 |
22/27 (81.48%) |
CA2;SLC4A1;ATP6V1D;...
|
| Retinol metabolism |
-1.73 |
2.83e-2 |
41/68 (60.29%) |
ADH7;DHRS9;CYP3A7;...
|
| Ascorbate and aldarate metabolism |
-1.77 |
2.11e-2 |
15/30 (50%) |
UGT2A3;ALDH1B1;UGT2B28;...
|
| Pentose and glucuronate interconversions |
-1.82 |
1.42e-2 |
17/34 (50%) |
AKR1B1;UGT2A3;RPE;...
|
| Sulfur metabolism |
-1.84 |
1.25e-2 |
9/10 (90%) |
TST;PAPSS1;SELENBP1;...
|
| Pyruvate metabolism |
-1.94 |
2.83e-3 |
41/47 (87.23%) |
FH;ME1;ACYP2;...
|
| Complement and coagulation cascades |
-1.95 |
3.78e-3 |
76/85 (89.41%) |
C1QA;C8B;C7;...
|
| Drug metabolism |
-2.05 |
2.83e-3 |
78/151 (51.66%) |
ADH7;FMO4;GSTA1;...
|
| Metabolism of xenobiotics by cytochrome P450 |
-2.34 |
0.00e+0 |
49/77 (63.64%) |
CYP2F1;GSTM2;UGT2A3;...
|
